Genomeditech(Shanghai) Co.LTD

EN

Insights

Resources

Current Position：Activity > News > Insights

Insights

GLP-1:Novo Nordisk submits for FDA approval of oral GLP-1 obesity drug

DLL4 Breakthrough in Cancer Therapy: Tovecimig Shows Promise for Biliary Tract Cancer!

TL1A：Teva and Sanofi Announce Duvakitug Positive Phase 2b Results Demonstrating Best-in-Class Potential in Ulcerative Colitis and Crohn’s Disease

IL-23:FDA approves Lilly's Omvoh® (mirikizumab-mrkz) for Crohn's disease, expanding its use to the second major type of inflammatory bowel disease

Amgen’s IMDYLLTRA®▼ (tarlatamab) Granted a Conditional Marketing Authorisation for Third-Line Treatment of Extensive-Stage Small Cell Lung Cancer in the United Kingdom

GLP:Eden Unveils the World's First Compounded GLP-1 Rx Gummy

TL1A:Teva and Sanofi Announce Duvakitug (Anti-TL1A) Positive Phase 2b Results Demonstrating Best-in-Class Potential in Ulcerative Colitis and Crohn’s Disease

Merck Enters into Exclusive Global GLP-1：License Agreement with Hansoh Pharma for Investigational Oral GLP-1 Receptor Agonist

ROR1：Merck Sharp & Dohme Initiates Phase III Clinical Trial of ROR1 ADC

HER2：FDA signs off on Merus' first-in-class NRG1+ cancer drug Bizengri

First Prev 3 4 5 6 7 Next Last

Total 7 Page

Jump

Current position：Activity > News > Insights

Classification

Insights

GLP-1:Novo Nordisk submits for FDA approval of oral GLP-1 obesity drug

DLL4 Breakthrough in Cancer Therapy: Tovecimig Shows Promise for Biliary Tract Cancer!

TL1A：Teva and Sanofi Announce Duvakitug Positive Phase 2b Results Demonstrating Best-in-Class Potential in Ulcerative Colitis and Crohn’s Disease

IL-23:FDA approves Lilly's Omvoh® (mirikizumab-mrkz) for Crohn's disease, expanding its use to the second major type of inflammatory bowel disease

Amgen’s IMDYLLTRA®▼ (tarlatamab) Granted a Conditional Marketing Authorisation for Third-Line Treatment of Extensive-Stage Small Cell Lung Cancer in the United Kingdom

GLP:Eden Unveils the World's First Compounded GLP-1 Rx Gummy

TL1A:Teva and Sanofi Announce Duvakitug (Anti-TL1A) Positive Phase 2b Results Demonstrating Best-in-Class Potential in Ulcerative Colitis and Crohn’s Disease

Merck Enters into Exclusive Global GLP-1：License Agreement with Hansoh Pharma for Investigational Oral GLP-1 Receptor Agonist

ROR1：Merck Sharp & Dohme Initiates Phase III Clinical Trial of ROR1 ADC

HER2：FDA signs off on Merus' first-in-class NRG1+ cancer drug Bizengri

MORE

Message consultation

                    
Toll-free hotline：400-627-9288
                    
Email address：mkt.genomeditech@gmail.com

Company address：5th Floor, Building 1, Lane 299, Kangwei Road, Pudong New District, Shanghai

Copyright © 2023 吉满生物科技（上海）有限公司 All rights reserved.

Message

Message consultation